Dopamine-prolactin Pathway Potentially Contributes to the Schizophrenia and Type 2 Diabetes Comorbidity

Overview

Journal Transl Psychiatry

Specialties Psychiatry
Public Health

Date 2016 Apr 20

PMID 27093067

Citations 13

Authors

C Gragnoli

G M Reeves

J Reazer

T T Postolache

Affiliations

Soon will be listed here.

Abstract

Schizophrenia (SCZ) and type 2 diabetes (T2D) are clinically associated, and common knowledge attributes this association to side effects of antipsychotic treatment. However, even drug-naive patients with SCZ are at increased risk for T2D. Dopamine dysfunction has a central role in SCZ. It is well-known that dopamine constitutively inhibits prolactin (PRL) secretion via the dopamine receptor 2 (DR2D). If dopamine is increased or if dopamine receptors hyperfunction, PRL may be reduced. During the first SCZ episode, low PRL levels are associated with worse symptoms. PRL is essential in human and social bonding, as well as it is implicated in glucose homeostasis. Dopamine dysfunction, beyond contributing to SCZ symptoms, may lead to altered appetite and T2D. To our knowledge, there are no studies of the genetics of the SCZ-T2D comorbidity focusing jointly on the dopamine and PRL pathway in the attempt to capture molecular heterogeneity correlated to possible disease manifestation heterogeneity. In this dopamine-PRL pathway-focused-hypothesis-driven review on the association of SCZ with T2D, we report a specific revision of what it is known about PRL and dopamine in relation to what we theorize is one of the missing links between the two disorders. We suggest that new studies are necessary to establish the genetic role of PRL and dopamine pathway in SCZ-T2D comorbidity.

Citing Articles

Metabolic syndrome in patients with schizophrenia: Underlying mechanisms and therapeutic approaches (Review).

Manta A, Georganta A, Roumpou A, Zoumpourlis V, Spandidos D, Rizos E Mol Med Rep. 2025; 31(5).

PMID: 40017113 PMC: 11894597. DOI: 10.3892/mmr.2025.13479.

Striatal dopamine gene network moderates the effect of early adversity on the risk for adult psychiatric and cardiometabolic comorbidity.

Barth B, Arcego D, de Mendonca Filho E, de Lima R, Parent C, Dalmaz C Sci Rep. 2024; 14(1):27349.

PMID: 39521843 PMC: 11550826. DOI: 10.1038/s41598-024-78465-5.

Sini San ameliorates lipid metabolism in hyperprolactinemia rat with liver-depression.

Xu W, Tian S, Mao G, Li Y, Qian H, Tao W Curr Res Food Sci. 2024; 9:100853.

PMID: 39328388 PMC: 11424950. DOI: 10.1016/j.crfs.2024.100853.

A systems biology approach for discovering the cellular and molecular aspects of psychogenic non-epileptic seizure.

Malekpour M, Jafari A, Kashkooli M, Salarikia S, Negahdaripour M Front Psychiatry. 2023; 14:1116892.

PMID: 37252132 PMC: 10213457. DOI: 10.3389/fpsyt.2023.1116892.

Recent findings on subjective well-being and physical, psychiatric, and social comorbidities in individuals with schizophrenia: A literature review.

He Y, Tanaka A, Kishi T, Li Y, Matsunaga M, Tanihara S Neuropsychopharmacol Rep. 2022; 42(4):430-436.

PMID: 35916310 PMC: 9773775. DOI: 10.1002/npr2.12286.

References

Terra L, Garay-Malpartida M, Wailemann R, Sogayar M, Labriola L . Recombinant human prolactin promotes human beta cell survival via inhibition of extrinsic and intrinsic apoptosis pathways. Diabetologia. 2011; 54(6):1388-97. DOI: 10.1007/s00125-011-2102-z. View

Albayrak Y, Beyazyuz M, Beyazyuz E, Kuloglu M . Increased serum prolactin levels in drug-naive first-episode male patients with schizophrenia. Nord J Psychiatry. 2013; 68(5):341-6. DOI: 10.3109/08039488.2013.839739. View

Mostafavi Abdolmaleky H, Nohesara S, Ghadirivasfi M, Lambert A, Ahmadkhaniha H, Ozturk S . DNA hypermethylation of serotonin transporter gene promoter in drug naïve patients with schizophrenia. Schizophr Res. 2014; 152(2-3):373-80. PMC: 7863587. DOI: 10.1016/j.schres.2013.12.007. View

Petronis A, Gottesman I, Kan P, Kennedy J, Basile V, Paterson A . Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance?. Schizophr Bull. 2003; 29(1):169-78. DOI: 10.1093/oxfordjournals.schbul.a006988. View

Park J, Stoffers D, Nicholls R, Simmons R . Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J Clin Invest. 2008; 118(6):2316-24. PMC: 2373422. DOI: 10.1172/JCI33655. View

Guigas B, de Leeuw van Weenen J, van Leeuwen N, Simonis-Bik A, van Haeften T, Nijpels G . Sex-specific effects of naturally occurring variants in the dopamine receptor D2 locus on insulin secretion and type 2 diabetes susceptibility. Diabet Med. 2014; 31(8):1001-8. DOI: 10.1111/dme.12464. View

Bob P, Fedor-Freybergh P, Jasova D, Bizik G, Susta M, Pavlat J . Dissociative symptoms and neuroendocrine dysregulation in depression. Med Sci Monit. 2008; 14(10):CR499-504. View

Hansen T, Ingason A, Djurovic S, Melle I, Fenger M, Gustafsson O . At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry. 2011; 70(1):59-63. DOI: 10.1016/j.biopsych.2011.01.031. View

van Nimwegen L, Storosum J, Blumer R, Allick G, Venema H, de Haan L . Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab. 2007; 93(2):572-7. DOI: 10.1210/jc.2007-1167. View

10.

Dai D, Cheng J, Zhou K, Lv Y, Zhuang Q, Zheng R . Significant association between DRD3 gene body methylation and schizophrenia. Psychiatry Res. 2014; 220(3):772-7. DOI: 10.1016/j.psychres.2014.08.032. View

11.

Nomiyama T, Tanaka Y, Piao L, Nagasaka K, Sakai K, Ogihara T . The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients. J Hum Genet. 2003; 48(3):138-41. DOI: 10.1007/s100380300021. View

12.

Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein H, Steiner J . The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry. 2014; 5:47. PMC: 4032934. DOI: 10.3389/fpsyt.2014.00047. View

13.

Williams H, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L . Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry. 2010; 16(4):429-41. PMC: 3918934. DOI: 10.1038/mp.2010.36. View

14.

Crow T, Poulter M, Lofthouse R, Chen G, Shah T, Bass N . Male siblings with schizophrenia share alleles at the androgen receptor above chance expectation. Am J Med Genet. 1993; 48(3):159-60. DOI: 10.1002/ajmg.1320480309. View

15.

Deserno L, Boehme R, Heinz A, Schlagenhauf F . Reinforcement learning and dopamine in schizophrenia: dimensions of symptoms or specific features of a disease group?. Front Psychiatry. 2014; 4:172. PMC: 3870301. DOI: 10.3389/fpsyt.2013.00172. View

16.

Godar S, Bortolato M . Gene-sex interactions in schizophrenia: focus on dopamine neurotransmission. Front Behav Neurosci. 2014; 8:71. PMC: 3944784. DOI: 10.3389/fnbeh.2014.00071. View

17.

Liu M, Zhang X, Du X, Fang Z, Liu Z, Xu Y . Severe disturbance of glucose metabolism in peripheral blood mononuclear cells of schizophrenia patients: a targeted metabolomic study. J Transl Med. 2015; 13:226. PMC: 4501123. DOI: 10.1186/s12967-015-0540-y. View

18.

Nohesara S, Ghadirivasfi M, Mostafavi S, Eskandari M, Ahmadkhaniha H, Thiagalingam S . DNA hypomethylation of MB-COMT promoter in the DNA derived from saliva in schizophrenia and bipolar disorder. J Psychiatr Res. 2011; 45(11):1432-8. DOI: 10.1016/j.jpsychires.2011.06.013. View

19.

Melas P, Rogdaki M, Osby U, Schalling M, Lavebratt C, Ekstrom T . Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. FASEB J. 2012; 26(6):2712-8. DOI: 10.1096/fj.11-202069. View

20.

Hales C, Barker D . The thrifty phenotype hypothesis. Br Med Bull. 2002; 60:5-20. DOI: 10.1093/bmb/60.1.5. View